The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I results from a phase I/II study of orteronel, an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC).
Daniel Peter Petrylak
Consultant or Advisory Role - Centicor; Millennium
Research Funding - Millennium
Anthony Mega
No relevant relationships to disclose
Jitendra G. Gandhi
No relevant relationships to disclose
William R. Clark
Research Funding - Alaska Clinical Research Center
Elisabeth I. Heath
Research Funding - Millennium
Jianqing Lin
No relevant relationships to disclose
William K. Oh
Consultant or Advisory Role - Amgen; Bellicum Pharmaceuticals; Dendreon; Medivation; Pfizer; Sanofi
David B. Agus
Consultant or Advisory Role - Millennium
Omer Kucuk
Research Funding - Millennium
Susan Moran
Employment or Leadership Position - Millennium
Stock Ownership - Millennium
Jingyuan Wang
Employment or Leadership Position - Millennium
Michael Bargfrede
Employment or Leadership Position - Millennium
Glenn Liu
No relevant relationships to disclose